|Synonyms||SAHA; Suberoyl anilide bishydroxamide; Suberoylanilide hydroxamic acid;|
|Solubility||Soluble in DMSO or ethanol. Almost insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Declaration||Manufactured by SynKinase.|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Vorinostat (SAHA, MK0683, Zolinza) inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.
- Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci: A. Munshi, et al.; Mol. Cancer Ther. 5, 1967 (2006)
- Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer: H.J. Vaughan, et al.; Mol. Ther. Oncolytics 21, 377 (2021)